Novartis’ Zolgensma, the world’s most expensive drug, was approved based on manipulated data. Despite being aware of issues, Novartis did not inform regulators until after the drug was approved.
Want to dig deeper into data and data integrity?
-
Podcast
Only Big Trust Propels Big Data into Big Discoveries
Listen Now
Dawn Barry -
Article
Evaluating the Completeness of ClinicalTrials.gov
Read Now
Stella Stergiopoulos, Kenneth A. Getz, Christine Blazynski
Therapeutic Innovation & Regulatory Science
Member-only content
-
Article
Cancer, Cloud Computing, and a National Research Data Ecosystem for Cancer
Read Now
Warren A. Kibbe
Global Forum -
Podcast
23 and Me: Information Empowering Patient Action
Listen Now
Emily Drabant Conley -
Article
Digital Disrupters Changing the Game?
Read Now
Adam Istas
Global Forum -
Article
Improving Clinical Data Quality and Trial Efficiency in China
Read Now
Charles Yan
Global Forum
Want to learn more?
Plan to attend our Global Clinical Trial Disclosure & Data Transparency Conference in Bethesda (MD) this September, or our European Clinical Trial Disclosure & Data Transparency Conference in Amsterdam in December.